

CLAIMS


1. A compound selected from the following compounds



;




; and



;


or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein the compound is a compound of Formula:




, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein the compound is a compound of Formula:



, or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1, wherein the compound is a compound of Formula:



, or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising the compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

6. The pharmaceutical composition of claim 5, wherein the pharmaceutical formulation is for subcutaneous, intramuscular, intravenous, oral, or inhalation administration.

7. The pharmaceutical composition of claims 5 or 6, wherein the pharmaceutical formulation is for oral administration.

8. Use of a compound of any one of the claims 1-4, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 5-7, in the manufacture of a medicament for treating or preventing a viral infection in a human in need thereof.

9. The use of claim 8, wherein the compound, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition, is to be administered to the human via oral, intramuscular, intravenous, subcutaneous, or inhalation administration.

10. The use of claims 8 or 9, wherein the compound, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition, is to be administered to the human with at least one additional therapeutic or prophylactic agent.

11. The use of claim 10, wherein the additional therapeutic or prophylactic agent is molnupiravir, oseltamivir, nirmatrelvir, or ritonavir.

12. The use of any one of claims 8-11, wherein the viral infection is a coronavirus infection.

13. The use of any one of claims 8-11, wherein the viral infection is a zoonotic coronavirus infection.

14. The use of any one of claims 8-11, wherein the viral infection is selected from the group consisting of 229E virus infection, NL63 virus infection, OC43 virus infection, and HKU1 virus infection.

15. The use of any one of claims 8-11, wherein the viral infection is SARS-CoV-2 infection (COVID-19).

16. The use of any one of claims 8-11, wherein the viral infection is a SARS-CoV virus infection or a MERS-CoV virus infection.

17. The use of any one of claims 8-11, wherein the viral infection is a pneumoviridae virus infection.

18. The use of claim 17, wherein the pneumoviridae virus infection is respiratory syncytial virus infection or a human metapneumovirus infection.

19. The use of any one of claims 8-11, wherein the viral infection is a picornaviridae virus infection, a flaviviridae virus infection, a filoviridae virus infection, an orthomyxovirus infection, or a paramyxoviridae virus infection.